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SGLT1 activity in lung alveolar cells 
of diabetic rats modulates airway 
surface liquid glucose concentration 
and bacterial proliferation
Tales Lyra Oliveira1,2, Návylla Candeia-Medeiros1, Polliane M. Cavalcante-Araújo1, 
Igor Santana Melo1, Elaine Fávaro-Pípi3, Luciana Alves Fátima4, Antônio Augusto Rocha2, 
Luiz Ricardo Goulart5,6, Ubiratan Fabres Machado4, Ruy R. Campos2 & Robinson Sabino-Silva7
High glucose concentration in the airway surface liquid (ASL) is an important feature of diabetes that 
predisposes to respiratory infections. We investigated the role of alveolar epithelial SGLT1 activity on 
ASL glucose concentration and bacterial proliferation. Non-diabetic and diabetic rats were intranasally 
treated with saline, isoproterenol (to increase SGLT1 activity) or phlorizin (to decrease SGLT1 activity); 
2 hours later, glucose concentration and bacterial proliferation (methicillin-resistant Sthaphylococcus 
aureus, MRSA and Pseudomonas aeruginosa, P. aeruginosa) were analyzed in bronchoalveolar lavage 
(BAL); and alveolar SGLT1 was analyzed by immunohistochemistry. BAL glucose concentration and 
bacterial proliferation increased in diabetic animals: isoproterenol stimulated SGLT1 migration to 
luminal membrane, and reduced (50%) the BAL glucose concentration; whereas phlorizin increased 
the BAL glucose concentration (100%). These regulations were accompanied by parallel changes of 
in vitro MRSA and P. aeruginosa proliferation in BAL (r = 0.9651 and r = 0.9613, respectively, Pearson 
correlation). The same regulations were observed in in vivo P. aeruginosa proliferation. In summary, 
the results indicate a relationship among SGLT1 activity, ASL glucose concentration and pulmonary 
bacterial proliferation. Besides, the study highlights that, in situations of pulmonary infection risk, such 
as in diabetic subjects, increased SGLT1 activity may prevent bacterial proliferation whereas decreased 
SGLT1 activity can exacerbate it.
The luminal surface of airway epithelium is covered by a thin layer of fluid, termed the airway surface liquid 
(ASL)1,2. The volume and composition of ASL are carefully regulated and play an important role in lung defense3. 
ASL glucose concentration is 3–20 times lower in ASL than in plasma4, and results from the balance of epi-
thelial glucose efflux and influx. Glucose flows from the interstitium to the ASL down its concentration gradi-
ent, through a paracellular pathway, in both proximal (trachea, bronchi and bronchioles) and distal (alveolar) 
lung5. On the other hand, ASL glucose uptake takes place in luminal membrane through the GLUT2-mediated 
facilitative glucose diffusion in proximal airways; and through the SGLT1-mediated sodium-dependent glucose 
transport in the distal lung6. It has been speculated that GLUT2-mediated glucose reabsorption depends on a 
concentration gradient generated by intracellular glucose metabolism1,7,8 and, probably, basolateral efflux does 
not occur at this proximal segment, since a glucose concentration gradient is unexpected. Differently, in the 
distal lung epithelium, glucose is transported against it gradient concentration, accumulates in the intracellular 
and thus can efflux into the interstitium by a facilitative transport9. Additionally, the SLC5A1 mRNA has also 
1Institute of Biological Sciences and Health, Federal University of Alagoas, Alagoas, Brazil. 2Department of 
Physiology, Federal University of São Paulo, São Paulo, Brazil. 3National Reference Center of Leprosy and Sanitary 
Dermatology, Federal University of Uberlandia, Minas Gerais, Brazil. 4Department of Physiology, Institute of 
Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil. 5Institute of Genetics and Biochemistry, Federal 
University of Uberlandia, Minas Gerais, Brazil. 6Department of Medical Microbiology and Immunology, University of 
California Davis, California, USA. 7Department of Physiology, Institute of Biomedical Sciences, Federal University of 
Uberlandia, Minas Gerais, Brazil. Correspondence and requests for materials should be addressed to R.S-S. (email: 
robinsonsabino@gmail.com)
Received: 02 July 2015
Accepted: 27 January 2016
Published: 23 February 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:21752 | DOI: 10.1038/srep21752
been identified in distal lung epithelium of animal and human epithelium1,10–12. The SGLT1 protein has been 
described on the surface of type I13 and type II14 pneumocytes. The instillation of phlorizin, an inhibitor of SGLT1 
cotransporter, decreased glucose reabsorption in rat lung in situ under normoglycemic conditions15, suggesting 
an important role of SGLT1 in ASL glucose homeostasis.
Hyperglycemia in diabetic patients is associated with elevated prevalence of respiratory complications16, and 
predisposes the host to bacterial infections1. The presence of high levels of glucose in ASL could predispose 
to respiratory infection through direct effects on bacterial growth1,6,17. Multiple respiratory pathogens such as 
methicillin-resistant Staphilococcos aureus (MRSA) and Pseudomonas aeruginosa (P. aeruginosa) are isolated 
more frequently from sputum of hyperglycemic critically ill patients, and that has been associated with increased 
glucose concentration in ASL3,18,19. Despite the direct effect of hyperglycemia on ASL glucose concentration, and 
consequently on bacterial proliferation, the capacity of the SGLT1 transporter to modulate these effects has never 
been investigated in diabetic condition.
The cAMP-PKA pathway mediates important effects of the non-selective beta-adrenergic agonist isopro-
terenol on pulmonary functions20. In SGLT1-transfected Xenopus laevis oocytes, as well as in epithelial cells 
of intestine and salivary glands, it has been clearly demonstrated that the activation of cAMP-PKA pathway 
enhances the SGLT1-mediated glucose transport, and that is related to the increased translocation of SGLT1 pro-
tein from the cytoplasm to the plasma membrane21–23. Because of that, we hypothesize that cAMP-PKA-mediated 
beta-adrenergic activity, induced by isoproterenol, might also increase ASL glucose reabsorption via SGLT1 in 
pneumocytes of distal lung.
Thus, the aims of the present study were to investigate: 1) the SGLT1 protein subcellular localization in alve-
olar cells; 2) the glucose concentration on bronchoalveolar lavage (BAL); 3) the proliferation of MRSA and 
P. aeruginosa on BAL, in lung from diabetic rats acutely treated (2 hours after intranasal infusion) with isoproter-
enol or phlorizin. Our findings related to the SGLT1 activity in the alveolar epithelium of diabetic rats open new 
perspectives for the development of drugs that can minimize or maximize respiratory infections, arising from 
regulation of glucose concentration in ASL.
Results
As proposed, non-diabetic (ND) and diabetic (D) rats were acutely treated with saline (s), isoproterenol (i), and 
phlorizin (p); thus, the following groups were studied: NDs, NDi, NDp, Ds, Di and Dp.
To confirm the effectiveness of intranasal isoproterenol treatment, hemodynamic parameters were assessed 
in animals anesthetized with sodium thiopental (Supplementary Figure 1). The results show that, 15 min after 
intranasal isoproterenol, there was an increase (P < 0.05) in mean arterial pressure and heart rate. These increases 
disappeared after ~70 min, evincing that when the lung or BAL were sampled (120 min), the cardiovascular effects 
of isoproterenol had already dissipated. Phlorizin treatment effectiveness was confirmed by alterations in ASL 
glucose concentration, as presented below.
Figure 1 shows that, as expected, diabetes reduced body weight (P < 0.05) and increased blood glucose levels 
(P < 0.05). Treatment of neither isoproterenol nor phlorizin altered these parameters.
Diabetes, isoproterenol and phlorizin do not change alveolar structures in rats. To determine 
whether diabetes, isoproterenol and phlorizin promoted morphostructural changes in lung, we stained the lung 
sections with hematoxylin-eosin. The alveolar and bronchiolar structures remained unaltered (Fig. 2A). Besides, 
treatments did not promote changes in inflammatory infiltrate, cell desquamation in lumen, epithelial thickening 
and interstitial fibrosis (Fig. 2B).
Diabetes, isoproterenol and phlorizin modulate mucus secretion. Mucus secretion in bronchiolar 
lumen is shown in Fig. 3. NDs, NDi and Di rats showed low mucus content; whereas the mucus content is clearly 
increased (Fig. 3A) in the other groups. The quantitative analysis (Fig. 3B) of PAS stained area related to the 
airway luminal area confirmed that diabetes increased mucus secretion (P < 0.05). Besides, the mucus content 
Figure 1. General parameters. Body weight (A) and blood glucose concentration (B) of non-diabetic 
saline (NDs), non-diabetic isoproterenol (NDi), non-diabetic phlorizin (NDp), diabetic saline (Ds), diabetic 
isoproterenol (Di) and diabetic phlorizin (Dp) treated rats. Results are mean ± SEM of 6–8 animals; *P < 0.05 vs 
NDs, #P < 0.05 vs NDi, and &P < 0.05 vs NDp; one-way ANOVA followed by Student Newman Keuls post-test.
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decreased after isoproterenol treatment in diabetic rats (Di vs Ds, P < 0.05), whereas it increased after phlorizin 
treatment in non-diabetic (NDp vs NDs, P < 0.05) and diabetic rats (Dp vs Ds, P < 0.05).
Subcellular distribution of SGLT1 protein in alveolar cells. Immunodetection of SGLT1 (green color) 
and F-actin (red color) in sections of rat pulmonary alveoli and in isolated alveolar cell is shown in Figs 4 and 5, 
respectively. Images from phlorizin-treated rats are presented as Supplementary Figure 2, since SGLT1 immuno-
detection after this treatment became almost imperceptible; thus, adding no relevant data.
Figure 4 shows the F-actin immunodetection in sections of pulmonary alveoli (4A to 4D), from which the 
squared marked alveolar septum was amplified and analyzed for F-actin (4E to 4H) and SGLT1 (4I to 4L), as well 
as for the merged image (orange to yellow colors, 4M to 4P). The SGLT1 was detected in the intracellular region 
(reserve pool) and in the luminal membrane as well. Merged images from isoproterol-treated NDi and Di rats 
depict yellow color as well as an outlined green color (4N and 4P) at the luminal region, suggesting increased 
SGLT1 translocation to the plasma membrane.
Figure 5 shows the immunoreactivity for F-actin (5A to 5D) and SGLT1 protein (5E to 5H), as well as the 
merged image (5I to 5L), in isolated alveolar cells of lung. In cells from NDs (5E) and Ds (5G) rats, SGLT1 protein 
is mainly detected in the intracellular region. The isoproterenol treatment (5F and 5H) promoted a strong reduc-
tion in the intracellular SGLT1 content, and that was accompanied by enhanced expression of SGLT1 in plasma 
membrane including the luminal surface. The coexpression of SGLT1 and F-actin, as evinced by the yellow color, 
reinforced the isoproterenol-induced SGLT1 mobilization from intracellular to plasma membrane (5J and 5L). 
No evident effects of diabetes on SGLT1 expression or subcellular distribution were observed.
Effect of isoproterenol and phlorizin on BAL glucose concentration of diabetic rats. Figure 6A 
shows the glucose concentration measured in BAL. Diabetes significantly increased the BAL glucose (Ds vs NDs, 
P < 0.05 ). Phlorizin treatment increased (P < 0.05) the BAL glucose in both non-diabetic and diabetic rats. 
Differently, isoproterenol treatment decreased the BAL glucose content in diabetic rats (P < 0.05), but had no 
effect on non-diabetic rats, in which the glucose concentration was already very low. The lung water content was 
Figure 2. Hematoxylin-eosin stained of lung tissue. Alveolar and bronchiolar structures in lung from non-
diabetic saline (NDs), non-diabetic isoproterenol (NDi), non-diabetic phlorizin (NDp), diabetic saline (Ds), 
diabetic isoproterenol (Di) and diabetic phlorizin (Dp) treated rats. Hematoxylin-eosin stained sections  
(A), magnification, x400, scale bar, 20 μ m, and potential histopathological alterations (B); present (+ ) and 
absent (− ). Images are representative of 4–6 animals in each group.
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also analyzed based on the measurement of the tissue wet/dry weight ratio; regulations similar to those observed 
in BAL glucose were observed (Fig. 6B).
Effects of isoproterenol and phlorizin on MRSA and P. aeruginosa proliferation in BAL of dia-
betic rats. To our knowledge, this is the first time that the proliferation of MRSA (Fig. 7A) and P. aeruginosa 
(Fig. 7B) in BAL of diabetic rats under intranasal treatment with saline, isoproterenol or phlorizin is described. In 
non-diabetic rats, isoproterenol treatment did not alter (P > 0.05) bacterial proliferation rate; however, phlorizin 
treatment increased (P < 0.05) the proliferation rate of MRSA and P. aeruginosa. Diabetes increased the bacte-
rial proliferation rate (Ds vs NDs, P < 0.05); and, in diabetic rats, isoproterenol treatment decreased (P < 0.05) 
whereas phlorizin treatment increased (P < 0.05) the bacterial proliferation of both MRSA and P. aeruginosa. 
Importantly, the Pearson correlation analysis shows that the mean values of MRSA (Fig. 7A) and P. aeruginosa 
(Fig. 7B) proliferation rates and the respective means values of BAL glucose concentration correlated positively 
(r = 0.9651 and r = 0.9613, respectively) and significantly (P < 0.05).
In order to evaluate whether these effects also occur in vivo, P. aeruginosa proliferation was analyzed in a 
homogenate of a whole pulmonary tissue sampled 6 hours after bacterial inoculation, with the same previous 
saline, isoproterenol and phlorizin treatments being applied 1 hour before inoculation and again reinforced 1 hour 
before euthanasia (Fig. 7C). The P. aeruginosa proliferation rate profile was exactly the same of that observed 
when P. aeruginosa was added to the BAL in vitro (Fig. 7B).
Figure 3. Periodic acid–Schiff (PAS) staining of lung tissue. Bronchiolar PAS stained sections of non-diabetic 
saline (NDs), non-diabetic isoproterenol (NDi), non-diabetic phlorizin (NDp), diabetic saline (Ds), diabetic 
isoproterenol (Di) and diabetic phlorizin (Dp) treated rats. (A) Photomicrographs of PAS stained lung; black 
arrows indicate the pink-magenta stained mucus in bronchiolar lumen; magnification, ×400, scale bar, 20 μ m. 
(B) Quantitative mucus production, expressed as mucus filled area related to total airway lumen area. Results 
are mean ± SEM of 4–6 animals; *P < 0.05 vs NDs; and #P < 0.05 vs Ds. One-way ANOVA followed by Student 
Newman Keuls post-test for mean comparisons.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:21752 | DOI: 10.1038/srep21752
Discussion
Depletion of ASL glucose is fundamental to guarantee the airway sterility in lung, and might prevent microbial 
infection in diabetic patients1. Modulation of the Na+-glucose coupled carrier SGLT1 activity, altering the ASL 
glucose concentration and the risk of respiratory infections, has not been tested yet. We showed that improve-
ment of SGLT1 activity by isoproterenol decreases ASL glucose concentration and microbial proliferation; and, 
conversely, repression of SGLT1 activity by phlorizin increases ASL glucose concentration and microbial prolif-
eration as well, in lung of diabetic rats.
Apparently, diabetes did not alter the SGLT1 content in pulmonary alveolar cells. However, the pre-treatment 
with isoproterenol clearly reduced the intracellular SGLT1 content, increasing its translocation to the luminal 
membrane; although not exclusively. Participation of β -adrenergic activity on subcellular SGLT1 localization has 
already been described in intestinal cells24, and in acinar and ductal cells of salivary glands23,25. For the first time, 
we here demonstrate the isoproterenol-induced SGLT1 migration from the intracellular to the luminal membrane 
of pulmonary alveolar cells. This finding predicts that isoproterenol, by increasing the SGLT1-mediated alveolar 
glucose re-uptake, can reduce the ASL glucose concentration.
Surprisingly, the pre-treatment with phlorizin virtually blocked all SGLT1 immunoreactivity mainly at the 
cell surface (Supplementary Figure 2). Certainly this result can not represent a 2-hour induced disappearance of 
the transporter. Regarding that, we point out recent studies that have characterized the molecular bases of the 
phlorizin binding domain in SGLT1 molecule26. Phlorizin binds at the 13rd transmembrane segment of SGLT1 
(Phe602 and Phe609); additionally, its sugar moiety binds in the D-glucose binding site (Gln457 and Thr460)27, 
which is close to the SGLT1 antibody binding domain (457 to 460 sequence). Thus, we propose that the phlorizin 
binding into SGLT1 should prevent the subsequent binding of the SGLT1 antibody, explaining the weakening of 
Figure 4. Immunodetection of SGLT1 protein in a section of rat pulmonary alveoli. Section of pulmonary 
alveoli from non-diabetic saline (NDs), non-diabetic isoproterenol (NDi), diabetic saline (Ds) and diabetic 
isoproterenol (Di) treated rats. Sections (A–D) were immunostained with anti-F-actin antibody (red). Enclosed 
boxes showing an alveolar septum, taken with a greater resolution, are presented in the next sections:  
(E–H) F-Actin (red), (I–L) SGLT1 (green) and (M–P) merged photomicrographs for colocalization of SGLT1 
and F-actin (yellow to orange). White arrows indicate the presence of SGLT1 in the luminal membrane. 
Description: (AL) alveolar lumen of the rat pulmonary section. Magnification, ×1000, scale bar, 10 μ m. Images 
are representative of 4–5 animals in each group.
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SGLT1 immunoreactivity in phlorizin-treated animals. However, it is important to highlight that the blocking of 
the glucose transport throughout SGLT1 (our goal) was certainly guaranteed, regardless of its immunodetection.
Glucose concentration in ASL is closely related to plasma glucose concentration in normoglycemic and hyper-
glycemic conditions3. According to the glucose concentration gradient, glucose diffuses from plasma to ASL 
through paracellular pathway, and that is increased under hyperglycemic condition1,3. Apparently, the SGLT1 
expression at the luminal membrane of alveolar cells of diabetic rats was unchanged; thus explaining why ASL 
glucose concentration increases: the increased plasma to ASL glucose flux is not counterbalanced by increased 
SGLT1-mediated re-uptake. According to that, in diabetic rats, when isoproterenol reduced the SGLT1 intracel-
lular and increased its expression at the luminal membrane of alveolar cells, decreased glucose concentration in 
Figure 5. Immunodetection of SGLT1 protein in lung alveolar cells. SGLT1 protein in lung alveolar 
cells from non-diabetic saline (NDs), non-diabetic isoproterenol (NDi), diabetic saline (Ds) and diabetic 
isoproterenol (Di) treated rats. (A–D) F-actin (red), (G,H) SGLT1 (green) and (I–L) merged photomicrographs 
for colocalization of SGLT1 and F-actin. White arrows indicate the presence of SGLT1 in the luminal 
membrane, and the asterisks indicate the presence of SGLT1 in the cytoplasm. Description: (LM) luminal 
membrane and (BM) basolateral membrane of the pneumocyte. Magnification, ×1000, scale bar, 2 μ m. Images 
are representative of 4–5 animals in each group.
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BAL was detected. On the other hand, the decrease of SGLT1 function in luminal membrane of alveolar cells after 
phlorizin treatment increased glucose concentration in BAL. Thus, the inversely parallel regulation of luminal 
SGLT1 function and glucose concentration of ASL points out that this transporter can be considered a new poten-
tial target for respiratory infection associated to higher levels of glucose in airway secretions.
Considering the capacity of SGLT1 to transport 264 molecules of water during the Na+/glucose transport 
cycle28–30, the increase in this protein at the luminal membrane of alveolar cells observed in isoproterenol-treated 
diabetic rats might be related to the decreased pulmonary water content verified in these animals; as well as 
the converse results observed in phlorizin-treated rats. Thus, the inversely parallel regulation of luminal SGLT1 
activity and pulmonary water content indicates that this transporter may also be involved in the regulation of 
ASL volume. Besides, comparing to the water pulmonary content, parallel regulations were observed in the bron-
chiolar mucus content, indicating an additional mechanism related to the total water pulmonary regulation. Yet, 
the diabetes-induced increase in total water content must include the osmotic effect of high interstitial glucose 
concentration, regardless of the mucus and ASL volume regulations.
Taking into account the considerations above, we are proposing that the SGLT1 activity as a fundamental 
modulator of the ASL glucose concentration in hyperglycemic states. Despite that, other potential involved mech-
anisms should be discussed. The facilitative glucose transporter GLUT2 participation should be ruled out, since 
this transporter has never been described in native lung alveolar cells yet7. Similarly, locally isoproterenol-induced 
changes in blood perfusion should also be ruled out, since its cardiovascular effects were transient, and did not 
alter blood glycemia, as showed in Supplementary Figure 1. Finally, participation of luminal mucus and/or ASL 
volumes needs to be disregarded in the BAL glucose regulation, since their regulations occurred in parallel. For 
instance, if the isoproterenol-induced decrease in mucus and/or water content were to alter glucose concentra-
tion, it should increase it, and not decrease it, as we observed.
ASL is normally sterile despite constant exposure to bacteria. The balance between bacterial growth and kill-
ing in ASL determines the outcome of exposure to inhaled or aspirated bacteria: infection or sterility1. Several 
studies have shown that acute hyperglycemia is associated with poor outcomes from hospital admission for pul-
monary infection. Patients with nosocomial pneumonia who have blood glucose concentration > 11 mmol/L 
show an increased risk of death and in-hospital complications compared with those with blood glucose concen-
tration ≤ 11 mmol/L18,31,32. Despite all reports that high blood glucose levels18 and/or high glucose concentration 
in bronchial aspirates31 predispose to pulmonary infection, the demonstration that short-time induced increase 
or decrease in BAL glucose parallels bacterial proliferation in diabetes has never been reported. Our data show 
the high correlation between mean BAL glucose concentration and MRSA and P. aeruginosa proliferation just 
2 hours after isoproterenol or phlorizin respiratory inhalation. Besides, in vivo 6-hour-induced proliferation of 
P. aeruginosa was similarly regulated. These data highlight the powerful role of the SGLT1 activity in modulating 
ASL glucose concentration, and, consequently, bacterial proliferation.
Interestingly, the present study is an alert to the potential risk of pulmonary infection in diabetic patients using 
SGLTs inhibitors to improve glycemic control. Rapidly, the pharmaceutical industry has supplied the market with 
SGLT2 inhibitors, as coadjuvant drugs for hyperglycemia treatment33. Besides, seeking to expanding their action 
mechanism, the dual SGLT2 and SGLT1 inhibitors, such as canagliflozin34 and LX421135, have been introduced 
in the diabetes pharmacopeia. However, whether systemically induced SGLT1 inhibition in diabetic patients is 
increasing pulmonary infection, especially in-hospital hyperglycemic subjects, has never been considered.
To the best of our knowledge, this is the first report to reveal that SGLT1 protein activity of the lung alveolar 
cells regulates the glucose concentration in the airway surface liquid and, consequently, the pulmonary bacterial 
proliferation risk, in diabetic state. Furthermore, the study unravels effects of β -adrenergic stimulation, which 
paves the way for new therapies able to prevent or fight pulmonary bacterial infection in diabetic patients. Finally, 
Figure 6. Bronchoalveolar lavage glucose concentration and lung water content. Bronchoalveolar lavage 
glucose concentration (A) and lung water content (B) were analyzed in samples from non-diabetic saline (NDs), 
non-diabetic isoproterenol (NDi), non-diabetic phlorizin (NDp), diabetic saline (Ds), diabetic isoproterenol 
(Di) and diabetic phlorizin (Dp) treated rats. Lung water content was estimated from the wet (W)/dry (D) tissue 
weight ratio. Results are mean ± SEM of 4–7 animals; *P < 0.05 vs NDs; #P < 0.05 vs Ds. One-way ANOVA 
followed by Student Newman Keuls post-test.
www.nature.com/scientificreports/
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the study contributes to revealing that in-hospital diabetic patients taking the dual SGLTs inhibitors are at very 
high risk of pulmonary infection, and drug withdrawal should be considered.
Methods
All experimental procedures were approved and conducted by the Ethical Committee for Animal Research of the 
Federal University of Alagoas (Approval No. 40/2012) and Ethical Committee for Animal Research of the Federal 
University of Sao Paulo (Approval No. 1281300915). All experimental protocols were conducted in accordance 
with the approved guidelines. Male Wistar rats (weighing ~260 g) were rendered diabetic (D) by a single intra-
venous injection of alloxan (40 mg/Kg body weight), and non-diabetic rats (ND) were injected with saline23,36. 
Animals were individually caged and allowed free access to water and standard rodent chow diet (Nuvilab CR-1; 
Nuvital, Curitiba, Brazil). ND and D rats were studied 21 days after diabetes induction. To demonstrate the effects 
of sympathetic activity and the inhibition of SGLT, ND and D rats were subjected to saline (0.9%; 100 μ L; NDs 
and Ds), isoproterenol (5 mg/kg; 100 μ L; NDi and Di) or phlorizin (10−3 M; 100 μ L; NDp and Dp) treatment 
2 hours before sampling. The treatments were performed intranasally, using a micropipette, and under anesthesia 
Figure 7. Bacterial proliferation analysis in bronchoalveolar lavage and lung tissue. Bacterial proliferation 
was analyzed in samples from non-diabetic saline (NDs), non-diabetic isoproterenol (NDi), non-diabetic 
phlorizin (NDp), diabetic saline (Ds), diabetic isoproterenol (Di) and diabetic phlorizin (Dp) rats. In vitro 
proliferation of methicillin-resistant Staphylococcus aureus (MRSA, panel A) and Pseudomonas aeruginosa 
(P. aeruginosa, panel B) were analyzed in bronchoalveolar lavage samples (BAL). Mean values of BAL glucose 
concentration (from Fig. 6) and of bacterial proliferation rate were analyzed by Pearson correlation test (panels 
C and D). In vivo P. aeruginosa proliferation was analyzed in lung tissue samples collected 6 hours after bacterial 
inoculation (panel E). Results are mean ± SEM of 4–6 animals; *P < 0.05 vs NDs, #P < 0.05 vs Ds; one-way 
ANOVA followed by Student Newman Keuls post-test.
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(60 mg/kg sodium thiopental, intraperitoneally). Blood, bronchoalveolar lavage, and tissue samples were always 
obtained from anesthetized rats, and in accordance with the approved guidelines.
Measurement of isoproterenol effects on the cardiovascular system. To confirm the effectiveness 
of isoproterenol treatment, non-diabetic rats were anesthetized with sodium thiopental (60 mg/kg, ip), and fitted 
with femoral arterial catheter. After at least 24 h of surgical recovery, mean arterial pressure (MAP) and heart rate 
(HR) were recorded in anesthetized rats, through an analog-digital board that communicated with PowerLab 
software (ADInstruments, Sydney, Australia). MAP and HR of ND and D rats were recorded for 10 minutes 
(baseline: time 0) and thereafter rats were treated with intranasal isoproterenol (5 mg/kg; 100 μ L). Cardiovascular 
records were followed for 2 hours. Additionally, blood samples were collected to evaluate glucose concentration 
at times zero and 2 hours.
Volume measurement of pulmonary water content. A lung fragment was removed, immediately 
weighed (wet-weight, W), placed in an oven at 40 °C for 24 hours, and reweighed (dry-weight; D). The W/D 
weight ratio was calculated as described previously37, and used to represent the total pulmonary water content38,39.
Collection of bronchoalveolar lavage (BAL) and tissue sampling. Following anesthesia, the chest 
cavity was accessed, to expose the lung and the trachea. A 19-gauge needle was gently inserted into the trachea, to 
inject 1 mL of chilled saline; thereafter, gentle aspirations were performed to collect 500 μ L of a bronchoalveolar 
lavage (BAL), which was immediately stored at − 20 °C for further analysis. Finally, the left ventricle was sec-
tioned, the lungs were exsanguinated by saline infusion throughout the right ventricle, and tissue samples were 
collected for further analysis.
Hematoxylin-eosin and periodic acid-Schiff staining of lung samples. Parts of the left lung were 
fixed with 4% formaldehyde prior to paraffin embedding to preserve the pulmonary architecture. Tissue sections 
were deparaffinized in xylol (xylene) and rehydrated through a graded series of ethanol to distilled water. Tissues 
were cut into 5-μ m sections for hematoxylin-eosin (HE) and periodic acid-Schiff staining (PAS) to evaluate his-
topathological profile and mucus production, respectively. Tissues were examined by light microscope (Olympus 
BX51 attached DP70 Digital Camera System). To quantify mucus production, ImageJ analyzer software (National 
Institutes of Health, Bethesda, MD USA) was used to calculate the percentage of the bronchiolar lumen area that 
was stained by PAS.
Immunohistochemistry analysis. Lung tissues were fixed in 4% formaldehyde phosphate buffer (PB) fol-
lowed by cryoprotection in increasing sucrose solutions (10%, 20% and 30%) in PB. Seven-μ m-thick sections 
were placed on gelatin-coated slides (Sigma Chem. Co., St Louis, USA), and subjected to immunodetection using 
anti-rat SGLT1 antibody (1:100, Merck Milipore, Germany, catalog number 07–1417 ), followed by incubation 
with Alexa Fluor 488 (1:200, Molecular Probes, Eugene, Oregon, USA, catalog number A21441). Reaction con-
trols consisted of non-inclusion of primary antibodies. F-actin staining was performed with rhodamin-phalloidin 
(1:100, Molecular Probes, Merck Milipore, Germany, catalog number R415). After washings, tissue sections were 
coverslipped and analyzed in a fluorescence microscope (Nikon Eclipse 50i). Images were recorded for further 
analysis using ImageJ Software (National Institutes of Health, Bethesda, MD USA). Selected images are represent-
ative of 4 animals in each group.
In vitro bacterial proliferation. Bronchoalveolar lavage (BAL) collected 2 hours after isoproterenol 
or phorizin treatment was used for the analysis of the in vitro bacterial proliferation. Methicillin-resistant 
Staphylococcus aureus - MRSA (ATCC BAA 976-1) and Pseudomonas aeruginosa (ATCC 27853-1) (bioMérieux) 
aliquots of 103 cells were mixed to 125 μ L of BAL, and samples of 1 μ L of the mixture were inoculated, in sterile 
conditions, in Petri dishes (90 mm) containing blood agar. Inoculation was performed in triplicate, in three dif-
ferent plates. The mean of the triplicate was considered as one sample, and the number of the samples (animals) 
is informed in the legend. The plates were incubated at 37 °C for 48 h. Bacterial cultures were quantified by speci-
fying the number of colony forming units (CFU), where each CFU was equivalent to 103 bacteria. The results are 
shown as CFU/μ L40.
In vivo P. aeruginosa proliferation. The bacterial inoculum used for pneumonia induction consisted of P. 
aeruginosa suspension (ATCC 27853) freshly prepared from an overnight blood agar culture. The optical density 
of the bacterial suspension was adjusted for 10 McFarland units (3.0 × 109 CFU/mL), according to the turbidity 
index41. Non-diabetic and diabetic rats were anaesthetized with isofluorane (0.08 to 1.5%), and an endotracheal 
intubation was performed, to instill 100 μ L of saline (0.9%), isoproterenol (5 mg/Kg) or phlorizin (10−3 M). After 
1 h, the animals were again subjected to endotracheal intubation, under anesthesia, to instill 200 μ L bolus of the 
bacterial inoculum41. Five hours (5 h) after bacterial inoculation, the animals were once more instilled with 100 uL 
of saline (0.9%), or isoproterenol (5 mg/Kg) or phlorizin (10−3 M). One hour after the last treatment (6 hours after 
the P. aeruginosa inoculation), the animals were anesthetized with a lethal dose of thiopental (200 mg/kg b.w., 
ip), the right lung was removed, homogenized in 10 mL of sterile saline, and 10-fold diluted. After that, aliquot 
of 100 μ L sample was added to 900 μ L of growth medium Luria-Bertani, and incubated under stirring at 37 °C 
for 22 h. Finally, the samples were analyzed by optical spectrophotometria (at 600 nm)1, and the results were con-
verted to McFarland units, and finally expressed as CFU/mL.
Analytical Procedures. Glucose concentration in BAL samples was measured using the COBAS Integra 400 
(Roche Diagnostics GmbH, Mannheim), with the Glucose HK Gen.3 assay (Roche Diagnosis)42. Blood glucose 
concentration was measured by a glucometer (Precision QID, MediSense, Sao Paulo, SP, Brazil).
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Statistical analysis. All values are reported as mean ± SEM. Number of animals is informed in the legends. 
Comparisons of the means were performed by one-way analysis of variance (ANOVA), followed by mean com-
parisons through the Student-Newman-Keuls post-test (GraphPad Prism version 5.00 for Windows, GraphPad 
Software, San Diego, CA, USA). The correlation between mean values of BAL glucose concentration and in vitro 
bacterial proliferation rate were analyzed by the Pearson correlation test. Values of P < 0.05 were considered as 
statistically significant.
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